Questions remain after FDA slimly approves Merk COVID antiviral pill

Federal health regulators slimly approved Merk's COVID-19 antiviral pill on Tuesday but questions still remain about the drugs efficacy amid the discovery of the Omicron variant. Director of the Penn Institute for Immunology Dr. John Wherry joins Good Day Philadelphia to discuss.

Top Videos